Select Page

APC-4000- Fluticasone DPI

If approved, APC-4000 will deliver Fluticasone as a dry powder for inhalation for the potential treatment of asthma. APC-4000 will be the first product by Adamis to use the Taper Dry Powder Inhalation (DPI) technology acquired from 3M Drug Delivery Systems. The Taper DPI is a patented pre-metered device that Adamis expects will have a number of potentially advantageous features including:

  • Greater efficiency
  • Less dependence on the individual’s aspiratory flow rate (due to the aerosolization energy inherent in the device)
  • Eliminated need for excipients in most formulations
  • Capability of delivering up to 120 doses (a two month supply)
  • Moisture protection
  • Ease of use
  • Design that reduces the likelihood of delivering a double dose

About the Taper DPI Technology Platform

As part of the acquisition agreement with 3M, Adamis has obtained worldwide rights to this Taper DPI platform technology in all indications in the dry powder inhalation field. The unique design uses proprietary 3M technology to store the active pharmaceutical ingredient (API) on a microstructured carrier tape. 3M will supply the drug delivery tape to Adamis under a separate supply agreement. In the future, Adamis intends to pursue other follow-on products using the Taper DPI patented technology platform with other formulations.

Potential Indication: Asthma/COPD

Asthma is a chronic lung disease that inflames and narrows the airways. Asthma causes recurring periods of wheezing, chest tightness, shortness of breath, and coughing. Asthma affects people of all ages, but it most often starts during childhood. In the United States, more than 25 million people are known to have asthma and about 7 million of these people are children. Chronic obstructive pulmonary disease, or COPD, is a progressive disease that makes it difficult to breathe. COPD can cause coughing that produces large amounts of mucus, wheezing, shortness of breath, chest tightness, and other symptoms. Cigarette smoking is the leading cause of COPD. Long term exposure to other irritants—such as air pollution, chemical fumes, or dust—also may contribute to COPD.